- Report
- October 2023
- 157 Pages
Global
From €5342EUR$5,500USD£4,564GBP
- Report
- March 2024
- 181 Pages
Global
From €3277EUR$3,374USD£2,800GBP
€3641EUR$3,749USD£3,111GBP
- Report
- February 2024
- 125 Pages
Global
From €5779EUR$5,950USD£4,937GBP
- Report
- December 2023
- 111 Pages
Global
From €5779EUR$5,950USD£4,937GBP
- Report
- December 2023
- 200 Pages
Global
From €4856EUR$5,000USD£4,149GBP
- Report
- December 2023
- 200 Pages
Global
From €4856EUR$5,000USD£4,149GBP
- Report
- January 2024
- 150 Pages
Global
From €4710EUR$4,850USD£4,024GBP
- Report
- May 2024
- 184 Pages
Global
From €4808EUR$4,950USD£4,107GBP
- Report
- September 2023
- 180 Pages
Global
From €5779EUR$5,950USD£4,937GBP
- Report
- March 2024
- 148 Pages
Global
From €3787EUR$3,899USD£3,235GBP
- Report
- November 2023
- 145 Pages
Global
From €2427EUR$2,499USD£2,074GBP
- Report
- February 2024
- 120 Pages
Global
From €4613EUR$4,750USD£3,941GBP
- Report
- August 2023
- 118 Pages
Global
From €7284EUR$7,500USD£6,223GBP
- Report
- October 2023
- 185 Pages
Global
From €4759EUR$4,900USD£4,066GBP
- Report
- November 2023
- 140 Pages
Global
From €4322EUR$4,450USD£3,692GBP
- Report
- November 2023
- 165 Pages
Global
From €2428EUR$2,500USD£2,074GBP
- Report
- February 2024
- 90 Pages
United States
From €4613EUR$4,750USD£3,941GBP
- Report
- September 2021
- 90 Pages
Global
From €874EUR$900USD£747GBP
- Report
- October 2021
- 154 Pages
Global
From €5390EUR$5,550USD£4,605GBP
- Report
- October 2022
- 216 Pages
Middle East
From €2040EUR$2,100USD£1,742GBP
€2914EUR$3,000USD£2,489GBP
Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases.
The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome.
Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more